Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-011 in first-line platinum-ineligible advanced or metastatic urothelial carcinoma
NL-OMON54684Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) and bladder cancer comparing Pembrolizumab + lenvatinib, Pembrolizumab + placebo and Open-label pembrolizumab monotherapy (3 arms). Primary endpoints: Progression-free survival and Overall survival. Started Nov 2019; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON54684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54684.